Paragon Bioservices announces contract for Marburg vaccine

Paragon Bioservices announced this week that it has been awarded $4.99 million dollars by the U.S. Army to assist the USAMRIID in developing vaccines against such diseases as Ebola Sudan, Ebola Zaire and Marburg virus.

These viruses are considered bioterror threats as they can be spread through aerosol methods.

The Marburg and Ebola viruses are a major health threat around the world as they cause hemorrhagic fever and lead to death in 90 percent of cases. As of yet, there are no therapies or vaccines available for these viruses. The viruses spread through bodily fluids and blood of infected patients who often succumb to hypovolemic shock.

“As a scientist and a business man, it is extremely rewarding to be part of an effort that may improve public health, as well as enhance national preparedness,” Marco Chacon, CEO of Paragon Bioservices said. “Preventing the spread of Ebola and Marburg Viruses is crucial to containing outbreaks and saving lives.”

The USAMRIID develops and strengthens production of these VLP-type vaccines and supports preclinical evaluation of the potency, safety and efficacy of these Filovirus vaccine candidates. Paragon will utilize their purification expertise and their wide-ranging VLP production to develop a larger-scale mammalian process to improve future GMP manufacturing.